-
-
-
-
-
-
-
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
-
-
-
-
-
-
-
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
-
-
-
-
-
-
-
TG Therapeutics secures $500 million credit facility, expands buyback
-
-
-
-
-
-
-
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
-
-
-
-
-
-
-
TG Therapeutics reports $616M 2025 revenue, targets $875-900M for 2026
-
-
-
-
-
-
-
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
-
-
-
-
-
-
-
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
-
1,168,812 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

